Navigation Links
Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session

SAN CARLOS, Calif., March 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that clinical data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) will be presented in a V-poster presentation at the of Cardiology (ACC) 56th Annual Scientific Session taking place in New Orleans, LA, March 24-27, 2007.

    The presentation details are as follows:


    Date/Time: Monday, March 26, 2007, 12:00 - 1:00 p.m. CDT


    Presentation Number: 1202-252


    Abstract Title: Safety and Tolerability of a Novel Tissue Factor/Factor

    VIIa Inhibitor rNAPc2 in Patients With Non-ST-Elevation Acute Coronary

    Syndrome Managed Invasively: Results From the ANTHEM/TIMI 32 Trial


    About V-Posters: V-posters are narrated by a prerecorded expert commentary

    and can be accessed by cell phone as attendees view the poster. The

    posters will remain on display for the entire length of the meeting.


    About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206, a preclinical candidate for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements" regarding the potential improvement or benefit that current and future clinical trial programs may demonstrate which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; and clinical development processes. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Annual Report on 10-K for the fiscal year ended December 31, 2006 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

CONTACT: Shelly Guyer, VP of Business Development & IR of Nuvelo, Inc.,+1-650-517-8437, ; or Danielle Bertrand of WeissCommPartners, +1-415-946-1056, , for Nuvelo, Inc. sguyer@nuvelo.com dbertrand@weiscommpartners.com

Web site: http://www.nuvelo.com/

Ticker Symbol: (NASDAQ-NMS:NUVO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... The University of Western States (UWS) ... 2016 National SACA Leadership Conference on the Portland campus September 23-25. The conference ... come together and develop skills to be future leaders in the profession. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... has found that more than 40 percent of participating fifth-grade students already have ... of Allergy and Asthma Clinical Research in the Division of Pulmonary, Allergy and ...
(Date:5/5/2016)... ... 2016 , ... In order to increase comfort, convenience and ... Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , a new ... app, developed for both smartphones and personal computers perfectly emulates that of the ...
(Date:5/5/2016)... ... 2016 , ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as its ... of experience within the healthcare revenue cycle industry. With a primary focus of end-to-end ... Financial Services at Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve the ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group ... today announced a new collaboration with Imerman Angels to expand outreach and ... the world. , “Imerman Angels provides an emotional lifeline to patients and families facing ...
Breaking Medicine News(10 mins):